NCT04515576View on ClinicalTrials.gov

A Study of LY3493269 in Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

March 9, 2021

Study Completion Date

March 9, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3493269

Administered SC

DRUG

Dulaglutide

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (3)

33143

Miami Research Associates, Miami

78229

Clinical Trials of Texas, Inc., San Antonio

92801

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04515576 - A Study of LY3493269 in Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter